Hypoglycaemia as a function of HbA1c in type 2 diabetes: Insulin glargine 300 U/mL in a patient‐level pooled analysis of EDITION 1, 2 and 3
Basal insulin therapy often involves a compromise between achieving glycaemic targets and avoiding hypoglycaemia, dependent on how intensively insulin is titrated. In the phase 3a EDITION 1, 2 and 3 studies, insulin glargine 300 U/mL (Gla‐300) provided equivalent glycaemic control to insulin glargine 100 U/mL (Gla‐100) with less hypoglycaemia in people with type 2 diabetes mellitus (T2DM). The current study evaluated the rates of confirmed (≤3.9 mmol/L [≤70 mg/dL]) or severe hypoglycaemia over 6 months of treatment with Gla‐300 or Gla‐100 in these EDITION studies, as a function of HbA1c. Analysis was performed on patient‐level data pooled from the three EDITION studies, and annualized hypoglycaemia rate as a function of HbA1c at month 6 was fitted using a negative binomial regression model. People treated with Gla‐300 experienced a consistently lower rate of confirmed (≤3.9 mmol/L [≤70 mg/dL]) or severe hypoglycaemia versus those treated with Gla‐100, regardless of HbA1c at month 6. The results suggest that treatment with Gla‐300 versus Gla‐100 could allow people with T2DM to achieve equivalent glycaemic control with less hypoglycaemia.
This article is protected by copyright. All rights reserved.
Publisher URL: https://onlinelibrary.wiley.com/doi/abs/10.1111/dom.13578
Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.
Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.